AOD-9604 in Passira — Fat Loss Peptide Research Guide
AOD-9604 research guide for Passira. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Unlike common nutraceuticals stocked in every health store, AOD-9604 reaches researchers through a specialist research supply market that Passira residents navigate through international suppliers. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers better verification tools than local retail ever could. Separating genuine research-grade AOD-9604 from the rest of the market requires three things: an HPLC chromatogram showing ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. This guide guides Passira researchers through that evaluation process and explains what quality documentation for AOD-9604 should look like.
How AOD-9604 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Passira comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying AOD-9604: Quality Markers to Look For
Before assessing any particular supplier, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. Signs of a credible vendor beyond COA quality: multi-year operating history, responsive technical support who understand testing methodology, and temperature-appropriate packaging with desiccant. For Passira researchers making a first AOD-9604 purchase: work through this evaluation framework first, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Passira
COA-verified · International tracking · Research grade
AOD-9604 is sold for research purposes only and is not approved for human consumption by the FDA or equivalent agencies worldwide — all information here is educational. Reconstitute AOD-9604 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — or 25mcg per insulin syringe unit. Quality AOD-9604 sourcing directly determines safety outcomes — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that rigorous vendor evaluation eliminates. For any individual considering AOD-9604 outside a formal research context: consult a qualified physician — this compound is unapproved for human therapeutic application and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
